Elevai Labs, Inc. Common Stock (ELAB) - Net Assets
Based on the latest financial reports, Elevai Labs, Inc. Common Stock (ELAB) has net assets worth $7.84 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($12.87 Million) and total liabilities ($5.03 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Elevai Labs, Inc. Common Stock's equity to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.84 Million |
| % of Total Assets | 60.9% |
| Annual Growth Rate | N/A |
| 5-Year Change | 1639.21% |
| 10-Year Change | N/A |
| Growth Volatility | 82.97 |
Elevai Labs, Inc. Common Stock - Net Assets Trend (2020–2025)
This chart illustrates how Elevai Labs, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of Elevai Labs, Inc. Common Stock to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Elevai Labs, Inc. Common Stock (2020–2025)
The table below shows the annual net assets of Elevai Labs, Inc. Common Stock from 2020 to 2025. For live valuation and market cap data, see ELAB stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $7.84 Million | +17.69% |
| 2024-12-31 | $6.66 Million | +74.01% |
| 2023-12-31 | $3.83 Million | +238.29% |
| 2022-12-31 | $1.13 Million | +151.05% |
| 2021-12-31 | $450.63K | +2010.33% |
| 2020-12-31 | $-23.59K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Elevai Labs, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2088007400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $8.00 | 0.00% |
| Other Comprehensive Income | $-2.34K | -0.03% |
| Other Components | $28.86 Million | 368.20% |
| Total Equity | $7.84 Million | 100.00% |
Elevai Labs, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Elevai Labs, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Infinity Mining Ltd
AU:IMI
|
$2.77 Million |
|
iMetal Resources Inc
V:IMR
|
$2.77 Million |
|
JPMorgan China Growth & Income PLC
LSE:JCGI
|
$2.77 Million |
|
Schroder Real Estate Investment Trust Ltd
LSE:SREI
|
$2.78 Million |
|
Rocky Mountain Liquor Inc
V:RUM
|
$2.77 Million |
|
Tlou Energy Ltd
AU:TOU
|
$2.76 Million |
|
Unity Biotechnology Inc
NASDAQ:UBX
|
$2.75 Million |
|
Hansa Trust
LSE:HAN
|
$2.75 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Elevai Labs, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,659,564 to 7,837,362, a change of 1,177,798 (17.7%).
- Net loss of 7,708,137 reduced equity.
- Share repurchases of 179 reduced equity.
- New share issuances of 2,917,409 increased equity.
- Other comprehensive income decreased equity by 2,002.
- Other factors increased equity by 5,970,707.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-7.71 Million | -98.35% |
| Share Repurchases | $179.00 | -0.0% |
| Share Issuances | $2.92 Million | +37.22% |
| Other Comprehensive Income | $-2.00K | -0.03% |
| Other Changes | $5.97 Million | +76.18% |
| Total Change | $- | 17.69% |
Book Value vs Market Value Analysis
This analysis compares Elevai Labs, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-0.21 | $1.43 | x |
| 2021-12-31 | $4.00 | $1.43 | x |
| 2022-12-31 | $9.97 | $1.43 | x |
| 2023-12-31 | $134.50 | $1.43 | x |
| 2024-12-31 | $7032.27 | $1.43 | x |
| 2025-12-31 | $385.09 | $1.43 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Elevai Labs, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -98.35%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1306.28%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.64x
- Recent ROE (-98.35%) is above the historical average (-106.30%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-220.55K |
| 2021 | -174.14% | -94889.84% | 0.00x | 1.48x | $-829.80K |
| 2022 | -159.13% | -234.94% | 0.40x | 1.67x | $-1.91 Million |
| 2023 | -112.40% | -251.17% | 0.33x | 1.36x | $-4.68 Million |
| 2024 | -93.79% | -253.14% | 0.27x | 1.35x | $-6.91 Million |
| 2025 | -98.35% | -1306.28% | 0.05x | 1.64x | $-8.49 Million |
Industry Comparison
This section compares Elevai Labs, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Elevai Labs, Inc. Common Stock (ELAB) | $7.84 Million | 0.00% | 0.64x | $2.77 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Elevai Labs, Inc. Common Stock
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the med… Read more